As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting ...
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.